All In Biotech

NDA 207695 · Anacor Pharms INC

Eucrisa

Crisaborole · Topical · Phosphodiesterase 4 Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Apr 3, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Dec 14, 2016

Approved uses

3

Original approval plus efficacy supplements

Registered trials

46

10 Phase 3, 1 recruiting

FAERS reports

9,605

734 serious, 25 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 23, 2025.

EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. EUCRISA is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. ( 1 )

Mechanism: Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 3, 2023 Supplement 12 · Efficacy LetterLabel
  • Mar 23, 2020 Supplement 10 · Efficacy · priority review LabelLetter
  • Dec 14, 2016 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • EUCRISA · CRISABOROLE 2% · OINTMENT, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Crisaborole" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,995
  • application site pain1,417
  • burning sensation987
  • off label use759
  • condition aggravated711
  • pruritus662
  • rash622
  • pain530
  • eczema469
  • dermatitis atopic455
  • erythema376
  • product use in unapproved indication341

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20141
20171,288
20182,074
20191,981
20201,051
2021497
2022941
2023675
2024528
2025371
2026197

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eucrisa (Crisaborole)

2024 spending

$9.3M

Beneficiaries

4,837

10,592 claims

Per beneficiary

$1,918

$11.90 per unit

View as table
YearSpending
2020$14,052,208
2021$11,744,648
2022$10,566,575
2023$10,407,692
2024$9,279,367

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 45 on PubMed

Sponsor: Anacor Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.